NOT-DA-15-046: Notice of the National Institute on Drug Abuse (NIDA) Participation in PAR-15-071 "Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)"

Notice of the National Institute on Drug Abuse (NIDA) Participation in PAR-15-071 "Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)"

Notice Number: NOT-DA-15-046

Key Dates
Release Date: February 24, 2015

Related Announcements
PAR-15-071

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in PAR-15-071 "Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)".

The following sections of PAR-15-071 have been updated to reflect NIDA's participation in this funding opportunity announcement.

Part 1. Overview Information

Components of Participating Organizations
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.853, 93.279

Part 2. Section VII. Agency Contacts

Scientific/Research Contact
Kristopher Bough, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-9800
Email: boughk@mail.nih.gov

Financial/Grants Management Contact
Pamela Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-253-8729
Email: pfleming@nida.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Kristopher Bough, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-9800
Email: boughk@mail.nih.gov